ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 0239 • ACR Convergence 2024

    Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Taissa M. Kasahara2, Asia-Sophia Wolf3, Kristin H. Bjørlykke4, Joseph Sexton5, Ingrid Jyssum5, Anne Therese Tveter5, Guri Solum3, Ingrid Fadum Kjønstad3, Andreas Lind6, Veselka Petrova Dimova-Svetoslavova6, Tore K. Kvien7, Jørgen Jahnsen8, Espen A. Haavardsholm1, Ludvig A. Munthe9, Sella A. Provan5, John Torgils Vaage9, Siri Mjaaland3, Kristin K. Jørgensen4, Gunnveig Grødeland9, Silje W. Syversen10 and Guro L. Goll10, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 3Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, 7Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 8Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 9Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
  • Abstract Number: 1146 • ACR Convergence 2024

    Impact of COVID-19 on Myositis Testing Trends

    Angel Kevin Garza-Elizondo1, Rosa Icela Arvizu-Rivera2, Pablo Gamez-Siller3, Daniela Alejandra Salcedo-Soto4, Jesus Cardenas-de la Garza5, Gisela Garcia-Arellano6, Miguel Angel Villarreal-Alarcon2 and Dionicio Galarza-Delgado7, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
  • Abstract Number: 2091 • ACR Convergence 2024

    Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic

    Derek Ochi1, Dagoberto Pina2, Manmeet Kaur3, Jeffery Fine4, Daniel Black5 and Barton Wise6, 1Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, 2School of Medicine, University of California Davis, Sacramento, CA, 3Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, 4Department of Public Health Sciences, University of California Davis, Sacramento, CA, 5Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, 6Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 1201 • ACR Convergence 2024

    Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study

    Minerva Nong1, Colby Lewis V2, Genna Braverman3, Vivian Bykerk3, Nathaniel Hupert2, Medha Barbhaiya3 and Lisa Mandl3, 1Hospital for Special Surgery, Tampa, FL, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
  • Abstract Number: 2182 • ACR Convergence 2024

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Lauren Arrigoni2, Kevin Rubenstein3, Max Wolff4, Mallory Barrix2, C. Jason Liang5, James Bost6, Meghan Delaney7, Luigi Notarangelo8, Karyl Barron9 and Roberta DeBiasi10, and PECOS Study Team, 1Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, 2Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, 3Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 4Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 5Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, 6Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, 7Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, 8Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, 9Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 10Children's National Hospital and Research Institute, Washington, DC

    Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…
  • Abstract Number: 0241 • ACR Convergence 2024

    Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients

    Rebecca Sadun1, Dan Crair1, Emmanuel Walter1, Eugene St.Clair2, David Pisetsky2, Amanda Eudy3, Megan Clowse4, Jennifer Rogers5, Kai Sun1, Lisa Criscione-Schreiber6, Mithu Maheswaranathan6, Jayanth Doss1, Sarah Valencia1 and M. Athony Moody7, 1Duke University, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Duke University, Raleigh, NC, 4Duke University, Chapel Hill, NC, 5Duke, Durham, NC, 6Duke University School of Medicine, Durham, NC, 7Duke University School of Medicine, Durham

    Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
  • Abstract Number: 1249 • ACR Convergence 2024

    Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

    Shilpa Venkatachalam1, Kelly Gavigan2, Erik Stone3, Angela Degrassi2, Laura Stradford4, David Curtis2, Esteban Rivera5 and Jeffrey Curtis6, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Long Island City, NY, 6University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
  • Abstract Number: 2198 • ACR Convergence 2024

    Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey

    Jonathan Hausmann1, Kevin Kennedy2, Ethan Knapp3, Nadine Lalonde4, jOhn Wallace5, Richard Howard6, Marcela Alvarez7, Mariana Fabi8, Lorena Franco9, Rebecca Grainger10, Jean Liew11, Pedro M Machado12, Zachary Wallace13, Jinoos Yazdany14 and Emily Sirotich15, and COVID-19 Global Rheumatology Alliance, 1Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 2McMaster University, Hamilton, ON, Canada, 3University of Connecticut School of Medicine, Farmington, CT, 4COVID-19 Global Rheumatology Alliance, London, ON, Canada, 5Covid 19 Global Rheumatology Alliance Patient Board, EDINBURGH, United Kingdom, 6Spondylitis Association of America, Encino, CA, 7CHIDRENS HOSPITAL DR. RICARDO GUTIERREZ ARGENTINA, Buenos Aires, Argentina, 8Argentine Society of Rheumatology, La Plata, Argentina, 9Argentine Society of Rheumatology, Cordoba, Argentina, 10University of Otago, Wellington, New Zealand, 11Boston University, Boston, MA, 12Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 13Massachusetts General Hospital, Newton, MA, 14UCSF, San Francisco, CA, 15Yale University, Vaughan, ON, Canada

    Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…
  • Abstract Number: 0242 • ACR Convergence 2024

    Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents

    Cassandra Calabrese1, Xiaofang wang2, Abhijit Duggal2, Gretchen Sacha2, Shuaiqi Huang2 and Leonard Calabrese2, 1Cleveland Clinic Foundation, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Immunocompromised patients constitute a high-risk group for severe COVID-19 outcomes and those on B cell depleting therapy (BCTD) are among the most vulnerable. Previous…
  • Abstract Number: 1531 • ACR Convergence 2024

    Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial

    Meggan Mackay1, Catriona Wagner2, Ashley Pinckney3, Jeffrey Cohen4, Zachary Wallace5, Arezou Khosroshahi6, Jeffrey Sparks7, Sandra Lord8, Amit Saxena9, Roberto Caricchio10, Alfred Kim11, Diane Kamen12, Fotios Koumpouras13, Anca Askanase14, Kenneth Smith15, Joel Guthridge15, Susan Macwana16, Sean McCarthy17, Matthew Sherman18, Sanaz Daneshfar Hamrah19, Maria Veri19, Kate York20, Sarah Walker21, Sandeep Narpala22, Robin Carroll22, Bob Lin22, Leonid Serebryanny22, Adrian McDermott23, William Barry21, Ellen Goldmuntz24, James McNamara25, Sara Tedeschi26, Amit Bar-Or27, Dinesh Khanna28, ACV01 Clinical Study Team15 and Judith James15, 1Feinstein Institutes for Medical Research, Manhasset, NY, 2Oklahoma Medical Research Foundation, Santa Cruz, CA, 3Rho, St Louis Park, NC, 4Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, 5Massachusetts General Hospital, Newton, MA, 6Emory University, Atlanta, GA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 8Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, 9NYU School of Medicine, New York, NY, 10University of Massachusetts Chan Medical School, Worcester, MA, 11Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 12Medical University of South Carolina, Charleston, SC, 13Yale School of Medicine, New Haven, CT, 14Columbia University Medical Center, New York, NY, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Oklahoma Medical Research Foundation, Oklahoma City, 17DAIT/NIAID/NIH, Rockville, MD, 18DAIT/NIAID/NIH, Washington, DC, 19Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, 20Rho Federal Systems Division, Durham, NC, USA., Durham, NC, 21Rho, Durham, NC, 22Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, 23Vaccine Research Center, NIH/NIAID, Bethesda, MD, 24NIAID/ NIH, Washington, DC, 25NIH, Bethesda, MD, 26Brigham and Women's Hospital, Boston, MA, 27Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, 28Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI

    Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…
  • Abstract Number: 2242 • ACR Convergence 2024

    A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis

    Mohammad Movahedi1, Elliot Hepworth2, Angela Cesta3, Xiuying Li3, Claire Bombardier4 and Sibel Aydin5, and OBRI investogators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3UHN, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Ottawa Hospital Research Institute, Ottawa, ON, Canada

    Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
  • Abstract Number: 0243 • ACR Convergence 2024

    Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment

    Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia

    Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
  • Abstract Number: 1718 • ACR Convergence 2024

    Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

    Amy Mudano1, Gary Cutter2, Emily Holladay3, Kevin Winthrop4, Ted Mikuls5, Geoffrey Thiele5, Mark Law5, Monique Bastidas6, Mike Zikry6, Kelly Chun6, Michael George7, Jayashree Sinha8, Naiara Alvarez9, John Tesser10 and Jeffrey Curtis11, and COVER Site Principal Investigator Group, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Edmond, OK, 4School of Medicine, Oregon Health and Science University, Portland, OR, 5University of Nebraska Medical Center, Omaha, NE, 6Labcorp, Calabasas, CA, 7University of Pennsylvania, Philadelphia, PA, 8self employed, Clovis, NM, 9Integrative Rheumatology of South Texas, McAllen, TX, 10Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 11University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Best practice for the use of immunosuppression to optimize vaccine response remains uncertain. We conducted the Covid VaccinE Response (COVER) trial, a multicenter, randomized…
  • Abstract Number: 2613 • ACR Convergence 2024

    Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study

    Gregory McDermott1, Ritu Gill2, Suzanne Byrne3, Staci Gagne3, Emily Kowalski3, Xiaosong Wang4, Grace Qian4, Katarina Bade3, Kevin Mueller3, Alene Saavedra3, Kathleen Vanni4, Caleb Bolden5, Naomi Patel5, Krishan Guzzo3, Marcy Bolster5, Shruthi Srivatsan5, Pierre-Antoine Juge6, Tracy J Doyle7, Zachary Wallace8 and Jeffrey Sparks9, 1Brigham and Women's Hospital, Brookline, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women’s Hospital, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 7Brigham and Women's Hospital, West Roxbury, MA, 8Massachusetts General Hospital, Newton, MA, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology